Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE)

Martin St John Sutton, Jeffrey Cerkvenik, Barry A Borlaug, Claude Daubert, Michael R Gold, Stefano Ghio, Julio A Chirinos, Cecilia Linde, Bonnie Ky, Martin St John Sutton, Jeffrey Cerkvenik, Barry A Borlaug, Claude Daubert, Michael R Gold, Stefano Ghio, Julio A Chirinos, Cecilia Linde, Bonnie Ky

Abstract

Background: Cardiac resynchronization therapy results in improved ejection fraction in patients with heart failure. We sought to determine whether these effects were mediated by changes in contractility, afterload, or volumes.

Methods and results: In 610 patients with New York Heart Association class I/II heart failure from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study, we performed detailed quantitative echocardiography assessment prior to and following cardiac resynchronization therapy. We derived measures of contractility (the slope [end-systolic elastance] and the volume intercept of the end-systolic pressure-volume relationship, stroke work, and preload recruitable stroke work), measures of arterial load and ventricular-arterial coupling, and measures of chamber size (volume intercept, end-systolic and end-diastolic volumes). At 6 and 12 months, cardiac resynchronization therapy was associated with a reduction in the volume intercept and end-systolic and end-diastolic volumes (P<0.01). There were no consistent effects on end-systolic elastance, stroke work, preload recruitable stroke work, or ventricular-arterial coupling. In the active cardiac resynchronization therapy population, baseline measures of arterial load were associated with the clinical composite score (odds ratio 1.30, 95% CI 1.04 to 1.63, P=0.02). The volume intercept was associated with mortality (hazard ratio 1.90, 95% CI 1.01 to 3.59, P=0.047) and more modestly with the combined end point of mortality or heart failure hospitalization (hazard ratio 1.48, 95% CI 0.8 to 2.25, P=0.06). In contrast, end-systolic elastance, stroke work, preload recruitable stroke work, and ventricular-arterial coupling were not associated with any outcomes.

Conclusion: In patients with NYHA Class I/II heart failure, cardiac resynchronization therapy exerts favorable changes in left ventricular end-systolic and end-diastolic volumes and the volume intercept. The volume intercept may be useful to gain insight into prognosis in heart failure.

Clinical trial registration: URL: https://www.clinicaltrials.gov/. Unique identifier: NCT00271154.

Keywords: cardiac resynchronization; echocardiography; heart failure.

© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

Figures

Figure 1
Figure 1
Schematic description of these measures of myocardial mechanics. The purple line denotes the end systolic pressure volume relationship (ESPVR), and the Ees represents the slope of the ESPVR. ESP denotes end-systolic pressure, and Eessb represents the noninvasively derived single-beat estimation of Ees. LVEDV is the end-diastolic volume, and LVESV is the end-systolic volume. V0 is the volume intercept of the ESPVR at an end-systolic pressure of 0 mm Hg. Ea represents the negative slope joining the end-systolic pressure-volume point to the point on the volume axis at end-diastole with this line denoted in orange. Stroke work is represented by the gray shaded region of the pressure-volume area. The dashed line within this region is the stroke volume (SV), or the difference between the LVEDV and LVESV. Ea indicates effective arterial elastance; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; SV, stroke volume; V0, volume intercept.
Figure 2
Figure 2
Changes in echocardiography parameters over 6 and 12 months. Mean values along with 95% CIs are presented according to CRT ON or CRT OFF for Ea, Eessb, Ea/Eessb, and V0. The numbers below each figure represent the number of participants in each subgroup (CRT OFF or CRT ON). The most pronounced changes were observed in V0. CRT indicates cardiac resynchronization therapy; CRT OFF, control group; CRT ON, active group; Ea, effective arterial elastance; Eessb, single beat–derived end-systolic elastance; V0, volume intercept.
Figure 3
Figure 3
Relationship between baseline V0 and time to first HF hospitalization or death in CRT ON. Kaplan–Meier plots (inverted) describing the relationship between V0 and time to first heart failure hospitalization or death in CRT ON alone. V0 expressed as quartiles. Q1 represents V0<−1.5 mL, Q2 represents −1.5 to 38 ml, Q3 represents 38 to 80.5 mL, and Q4 represents >80.5 mL. CRT indicates cardiac resynchronization therapy; CRT ON, active group; HF, heart failure; Q, quartile; V0, volume intercept.

References

    1. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA, III, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–1338.
    1. St John Sutton M, Ghio S, Plappert T, Tavazzi L, Scelsi L, Daubert C, Abraham WT, Gold MR, Hassager C, Herre JM, Linde C REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) Study Group. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009;120:1858–1865.
    1. Borlaug BA, Kass DA. Invasive hemodynamic assessment in heart failure. Heart Fail Clin. 2009;5:217–228.
    1. Borlaug BA, Kass DA. Ventricular-vascular interaction in heart failure. Heart Fail Clin. 2008;4:23–36.
    1. Linde C, Abraham WT, Gold MR, Daubert C REVERSE Study Group. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol. 2010;56:1826–1831.
    1. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834–1843.
    1. Linde C, Gold M, Abraham WT, Daubert JC REVERSE Study Group. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure—the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Am Heart J. 2006;151:288–294.
    1. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ Chamber Quantification Writing G, American Society of Echocardiography’s Guidelines and Standards, Committee, European Association of E. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group. J Am Soc Echocardiogr. 2005;18:1440–1463.
    1. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR, Loh E, Kocovic DZ, Fisher WG, Ellestad M, Messenger J, Kruger K, Hilpisch KE, Hill MR Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107:1985–1990.
    1. Ky B, French B, May Khan A, Plappert T, Wang A, Chirinos JA, Fang JC, Sweitzer NK, Borlaug BA, Kass DA, St John Sutton M, Cappola TP. Ventricular-arterial coupling, remodeling, and prognosis in chronic heart failure. J Am Coll Cardiol. 2013;62:1165–1172.
    1. Chen CH, Fetics B, Nevo E, Rochitte CE, Chiou KR, Ding PA, Kawaguchi M, Kass DA. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J Am Coll Cardiol. 2001;38:2028–2034.
    1. Borlaug BA, Redfield MM, Melenovsky V, Kane GC, Karon BL, Jacobsen SJ, Rodeheffer RJ. Longitudinal changes in left ventricular stiffness: a community-based study. Circ Heart Fail. 2013;6:944–952.
    1. Lee WS, Huang WP, Yu WC, Chiou KR, Ding PY, Chen CH. Estimation of preload recruitable stroke work relationship by a single-beat technique in humans. Am J Physiol Heart Circ Physiol. 2003;284:H744–H750.
    1. Park RC, Little WC, O’Rourke RA. Effect of alteration of left ventricular activation sequence on the left ventricular end-systolic pressure-volume relation in closed-chest dogs. Circ Res. 1985;57:706–717.
    1. Little WC, O’Rourke RA. Effect of regional ischemia on the left ventricular end-systolic pressure-volume relation in chronically instrumented dogs. J Am Coll Cardiol. 1985;5:297–302.
    1. Zanon F, Aggio S, Baracca E, Pastore G, Corbucci G, Boaretto G, Braggion G, Piergentili C, Rigatelli G, Roncon L. Ventricular-arterial coupling in patients with heart failure treated with cardiac resynchronization therapy: may we predict the long-term clinical response? Eur J Echocardiogr. 2009;10:106–111.
    1. Zocalo Y, Bia D, Armentano RL, Gonzalez-Moreno J, Varela G, Calleriza F, Reyes-Caorsi W. Resynchronization improves heart-arterial coupling reducing arterial load determinants. Europace. 2013;15:554–565.
    1. Knappe D, Pouleur AC, Shah AM, Cheng S, Uno H, Hall WJ, Bourgoun M, Foster E, Zareba W, Goldenberg I, McNitt S, Pfeffer MA, Moss AJ, Solomon SD Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy Investigators. Dyssynchrony, contractile function, and response to cardiac resynchronization therapy. Circ Heart Fail. 2011;4:433–440.
    1. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670–679.

Source: PubMed

Подписаться